This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2007 by Grewal Eye Institute.
Recruitment status was:  Recruiting
Information provided by:
Grewal Eye Institute Identifier:
First received: April 30, 2007
Last updated: June 1, 2007
Last verified: June 2007
This study analyzes the safety and efficacy of off-label Subconjunctival Injection of bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following glaucoma filtration surgery.

Condition Intervention Phase
Glaucoma Drug: Subconjunctival Bevacizumab Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery.

Resource links provided by NLM:

Further study details as provided by Grewal Eye Institute:

Primary Outcome Measures:
  • IOP < 18mmHg without anti- glaucoma medications at 6 months follow up after surgery or at least a 20% reduction from baseline IOP. [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • adverse reaction to bevacizumab at site of injection [ Time Frame: 6 months ]

Estimated Enrollment: 40
Study Start Date: May 2007
Estimated Study Completion Date: December 2007
  Show Detailed Description


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 40 years or over.
  2. Patient with uncontrolled intraocular pressure on maximum tolerated medical therapy (both primary open angle and primary angle closure glaucoma), requiring trabeculectomy.
  3. Indications for surgery are based on our own practice patterns: (1) IOP values that are associated with high probability of glaucoma progression and (2) deterioration of the visual field or changes of the optic disk that is compatible with progressive glaucomatous damage, as judged by the examining physician.
  4. No history of prior surgical procedure like trabeculectomy, cataract surgery, posterior segment surgery etc.
  5. Subject able and willing to cooperate with investigation plan.
  6. Subject able and willing to complete postoperative follow-up requirements.
  7. Subject willing to sign informed consent form.

Exclusion Criteria:

  1. Known allergic reaction to mitomycin-C/ bevacizumab.
  2. Subject is on warfarin and discontinuation is not recommended.
  3. Normal tension glaucoma.
  4. Participation in an investigational study during the 30 days preceding trabeculectomy
  5. Patients who had undergone major surgery utpo 28 days before.
  6. Ocular infection within 14 days prior to trabeculectomy.
  7. Pregnant or breast-feeding women.
  8. Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00468429

Contact: Rajeev Jain, MD +91-172-5056969
Contact: Dilraj S Grewal, MBBS +91-172-5056969

Grewal Eye Institute Recruiting
Chandigarh, India, 160009
Contact: Dilraj S Grewal, MBBS    +91-172-5056969   
Principal Investigator: Dilraj S Grewal, MBBS         
Sponsors and Collaborators
Grewal Eye Institute
Principal Investigator: Rajeev Jain, MD Grewal Eye Institute
Study Chair: SPS Grewal, MD Grewal Eye Institute
Study Director: Gagandeep S Brar, MD Grewal Eye Institute
Study Director: Dilraj S Grewal, MBBS Grewal Eye Institute
  More Information Identifier: NCT00468429     History of Changes
Other Study ID Numbers: GEI-00001
Study First Received: April 30, 2007
Last Updated: June 1, 2007

Keywords provided by Grewal Eye Institute:
Glaucoma Filtration Surgery
Mitomycin C
Intraocular Pressure

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antibiotics, Antineoplastic
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017